Audiologic Assessment and Management of Teprotumumab-Associated Ototoxicity: An Updated Narrative Review
{{output}}
Introduction: Teprotumumab (Tepezza®), an insulin-like growth factor-1 receptor (IGF-1R) antagonist, is the first FDA-approved targeted therapy for thyroid eye disease (TED). While effective for reducing proptosis and inflammation, increasing post-marketing e... ...
